HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, ...

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from ...

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® ...

Reports Q4 revenue $7.68M vs $0 last year. “We are off to a strong start with the U.S. launch of Revuforj and are very encouraged by the early ...

Syndax Pharmaceuticals Inc. ( ($SNDX) ) has released its Q4 earnings. Here is a breakdown of the information Syndax Pharmaceuticals Inc. presented ...

Syndax Pharmaceuticals reported strong early results for its newly launched products, achieving $7.7 million in net revenue from Revuforj® (revumenib) in just five weeks following its U.S. launch.

WALTHAM, Mass. — WALTHAM, Mass. — Syndax Pharmaceuticals Inc. (SNDX) on Monday reported a loss of $94.2 million in its fourth quarter. On a per-share basis, the Waltham, Massachusetts-based company ...

[Operator Instructions] At this time, I'd like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals. Thank you, operator. Welcome, and thank you all for ...